Publicacións nas que colabora con Borja Ibáñez Cabeza (40)

2024

  1. Colchicine in acute heart failure: Rationale and design of a randomized double-blind placebo-controlled trial (COLICA)

    European Journal of Heart Failure

2023

  1. Bleeding and embolic risk in patients with atrial fibrillation and cancer

    Revista Espanola de Cardiologia, Vol. 76, Núm. 5, pp. 344-352

  2. Diferencias regionales en la atención al IAMCEST en España. Datos del Registro de Código Infarto ACI-SEC

    REC: Interventional Cardiology, Vol. 5, Núm. 2, pp. 118-128

2022

  1. Analysis of the management of ST-segment elevation myocardial infarction in Spain. Results from the ACI-SEC Infarction Code Registry

    Revista Espanola de Cardiologia, Vol. 75, Núm. 8, pp. 669-680

  2. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up

    European Heart Journal, Vol. 43, Núm. 11, pp. 1059-1103

  3. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    Cardiovascular research, Vol. 118, Núm. 6, pp. 1385-1412

  4. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    European Heart Journal, Vol. 43, Núm. 11, pp. 1033-1058

  5. Nutrition status, obesity and outcomes in patients with atrial fibrillation

    Revista Espanola de Cardiologia, Vol. 75, Núm. 10, pp. 826-833

  6. Polypill Strategy in Secondary Cardiovascular Prevention

    The New England journal of medicine, Vol. 387, Núm. 11, pp. 967-977

  7. Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial

    European Journal of Heart Failure, Vol. 24, Núm. 3, pp. 581-588

  8. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT)

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 3, pp. 291-301

  9. Short-term mortality differs between men and women according to the presence of previous cardiovascular disease: Insights from a nationwide STEMI cohort

    International Journal of Cardiology, Vol. 367, pp. 90-98

  10. Trade-off between the effects of embolic versus bleeding events on mortality in elderly patients with atrial fibrillation

    Revista Espanola de Cardiologia, Vol. 75, Núm. 4, pp. 334-342

2021

  1. Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI)

    Basic Research in Cardiology, Vol. 116, Núm. 1

  2. Glycated Hemoglobin and Subclinical Atherosclerosis in People Without Diabetes

    Journal of the American College of Cardiology, Vol. 77, Núm. 22, pp. 2777-2791

  3. In-hospital outcomes of COVID-19 ST-elevation myocardial infarction patients

    EuroIntervention, Vol. 16, Núm. 17, pp. 1426-1433

  4. Mitral valve prolapse morphofunctional features by cardiovascular magnetic resonance: more than just a valvular disease

    Journal of Cardiovascular Magnetic Resonance, Vol. 23, Núm. 1

  5. The Art of Prescribing β-Blockers After Myocardial Infarction

    Circulation: Cardiovascular Interventions, Vol. 14, Núm. 4, pp. E010720

  6. Triglycerides and Residual Atherosclerotic Risk

    Journal of the American College of Cardiology, Vol. 77, Núm. 24, pp. 3031-3041

2020

  1. Impact of COVID-19 on ST-segment elevation myocardial infarction care. The Spanish experience

    Revista Espanola de Cardiologia, Vol. 73, Núm. 12, pp. 994-1002